Vaccinex, Inc. to Provide Clinical Data on Posters Presented at the 2019 Annual Meeting of the American Association for Cancer Research (AACR)
April 01, 2019 08:00 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., April 01, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and...
Vaccinex, Inc. to Present at the Oppenheimer & Co. 29th Annual Healthcare Conference on March 19, 2019
March 13, 2019 08:30 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., March 13, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and...
Vaccinex Reports Fourth Quarter 2018 Financial Results and Provides Corporate Update
March 13, 2019 07:16 ET
|
Vaccinex, Inc.
Initial data from ongoing open label study of pepinemab (VX15/2503) in combination with avelumab in non-small cell lung cancer expected in 2Q 2019 Enrollment in cohort B of the Phase 2 SIGNAL...
Vaccinex, Inc. to Present Data on Its Anti-SEMA4D Compound at the American Association for Cancer Research Annual Meeting 2019
March 06, 2019 08:30 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., March 06, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to...
Vaccinex, Inc. Presented Previously Disclosed Data from Ongoing Phase 1/2 Trial of VX15/2503 (Pepinemab) in Huntington’s Disease (the “SIGNAL Trial”) at Cambridge Healthtech Institute’s 18th Annual PepTalk
January 17, 2019 08:30 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Jan. 17, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat...
Vaccinex, Inc. Announces Completion of Enrollment for Its “SIGNAL” Huntington’s Disease Trial
January 16, 2019 08:30 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Jan. 16, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) announced today that it has completed subject enrollment for the SIGNAL trial. SIGNAL is a Phase 2, multi-center,...
Preclinical Data on Vaccinex, Inc. Anti-SEMA4D Monoclonal Antibody in Combination with Checkpoint Inhibitors Published in Cancer Immunology Research
December 12, 2018 08:30 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Dec. 12, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat...
Vaccinex, Inc. Gives Podium Presentation and Poster at the Society for Immunotherapy of Cancer Annual Meeting
November 15, 2018 08:30 ET
|
Vaccinex, Inc.
Company Reviews Mechanism of Action, Preclinical Outcomes and Phase 1 Safety Results of VX15 (pepinemab) as Single Agent and In Combination Therapy Against Multiple Cancers ROCHESTER, N.Y., Nov. 15,...
Vaccinex Reports Third Quarter 2018 Financial Results and Provides Corporate Update
November 13, 2018 07:58 ET
|
Vaccinex, Inc.
Lead candidate pepinemab (VX15) being evaluated in three ongoing clinical trials in cancer and Huntington’s Disease Enrollment in CLASSICAL Lung Cancer trial and Cohort B of the SIGNAL Huntington’s...
Vaccinex, Inc. Presents Overview of the Clinical Development of VX15 (pepinemab) for the Potential Treatment of Huntington’s Disease at the Huntington Study Group’s 2018 Annual Meeting
November 12, 2018 08:30 ET
|
Vaccinex, Inc.
Presentation and Poster Include Previously Announced Results of Cohort A of SIGNAL Trial ROCHESTER, N.Y., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage...